Holen Sie sich die Stockscreener-App
162.05
0.12%
0.20
Schlusskurs vom Vortag:
$161.85
Offen:
$161.85
24-Stunden-Volumen:
676.14K
Relative Volume:
0.83
Marktkapitalisierung:
$12.50B
Einnahmen:
$8.27B
Nettoeinkommen (Verlust:
$173.28M
KGV:
74.64
EPS:
2.1712
Netto-Cashflow:
$785.90M
1W Leistung:
-5.97%
1M Leistung:
+1.38%
6M Leistung:
+41.91%
1J Leistung:
-16.02%
1-Tages-Spanne:
$160.41
$163.43
1-Wochen-Bereich:
$160.41
$176.70
52-Wochen-Spanne:
$66.57
$203.91
Icon Plc Stock (ICLR) Company Profile
Firmenname
Icon Plc
Sektor
Branche
Telefon
-
Adresse
-
Compare ICLR vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
162.05 | 13.30B | 8.27B | 173.28M | 785.90M | 2.1712 |
TMO
Thermo Fisher Scientific Inc
|
654.80 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
214.06 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
410.35 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
167.78 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
258.21 | 44.50B | 16.63B | 1.39B | 2.12B | 8.0674 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2026-02-23 | Hochstufung | Jefferies | Hold → Buy |
| 2026-02-18 | Hochstufung | TD Cowen | Hold → Buy |
| 2026-02-17 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2026-02-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2026-02-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-01-08 | Herabstufung | Truist | Buy → Hold |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2025-09-09 | Herabstufung | Jefferies | Buy → Hold |
| 2025-09-03 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2025-08-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-07-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-04-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-04-14 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-04-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-09-18 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2023-12-15 | Eingeleitet | Truist | Buy |
| 2023-09-13 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-17 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-01-13 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-11-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-09-07 | Eingeleitet | UBS | Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-05-24 | Eingeleitet | Guggenheim | Buy |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2021-09-27 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-14 | Eingeleitet | Citigroup | Neutral |
| 2021-04-13 | Fortgesetzt | BofA Securities | Neutral |
| 2021-04-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-03-08 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-03-03 | Eingeleitet | Barclays | Equal Weight |
| 2021-03-01 | Hochstufung | UBS | Neutral → Buy |
| 2021-02-26 | Hochstufung | Truist | Hold → Buy |
| 2020-07-24 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-04-20 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Hold |
| 2020-01-27 | Herabstufung | SunTrust | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-09-23 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-07-26 | Hochstufung | UBS | Sell → Neutral |
| 2019-01-25 | Hochstufung | Mizuho | Neutral → Buy |
| 2018-10-26 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-10-09 | Eingeleitet | UBS | Sell |
| 2018-04-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-15 | Bestätigt | Mizuho | Neutral |
| 2018-01-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-10-27 | Bestätigt | Barclays | Equal Weight |
| 2017-09-11 | Eingeleitet | BofA/Merrill | Buy |
| 2017-07-31 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-27 | Bestätigt | Mizuho | Neutral |
| 2017-06-29 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Icon Plc Aktie (ICLR) Neueste Nachrichten
Hybrid Clinical Research Associate Job at ICON | Apply Online Here - BioTecNika
UBS Restarts Coverage of Icon PLC (ICLR) with Neutral Rating and $195 Price Target - GuruFocus
Hybrid Clinical Research Job Opening at ICON plc | Apply Online Here - BioTecNika
A Look at Icon PLC (ICLR) After 6.1% Gain -- GF Value $205.79 vs Price $173.90 - GuruFocus
ICON Plc (ICLR) Rises as Investors Appear to Lean on Backlog, Guidance, and Recent Filings - Moomoo
ICON plc (ICLR) rises as investors appear to lean on backlog, guidance, and recent filings - Quiver Quantitative
ICON Public Limited Company’s (ICLR) Shrinking Moat Warranted an Early Departure - Yahoo Finance
Icon PLC (ICLR) Stock Up 3.3% and Still Undervalued -- GF Score: 95/100 - gurufocus.com
Rare Disease Contract Research Organization (CRO) Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook - GlobeNewswire Inc.
ICON plc stock edges higher after analyst updates and steady Q2 figures - AD HOC NEWS
Icon PLC (ICLR) Stock Down 3.3% -- Now Undervalued? GF Score: 96/100 - GuruFocus
Citi Maintains Icon PLC(ICLR.US) With Hold Rating, Raises Target Price to $175 - Moomoo
ICLR Maintained by Citigroup -- Price Target Lowered to $175 - GuruFocus
Strategic Sale: DR JOHN CLIMAX Decides To Exercise Options Worth $204K At Icon - Benzinga
ICON PLC Director Eugene McCague Exercises Stock Options and Sells Shares on September 17, 2026 - kalkinemedia.com
S&P 500 Futures Rise in Premarket Trading; Xenon Pharmaceuticals, Icon PLC Lag - Barron's
Icon (ICLR) insider sells 5,005 shares after exercising options - Stock Titan
Director at ICON (ICLR) unloads stock right after exercising options - Stock Titan
Director at ICON (NASDAQ: ICLR) exercises options, then sells 5,005 shares - Stock Titan
Truist Financial Maintains Icon PLC(ICLR.US) With Buy Rating - Moomoo
ICON PLC (NASDAQ: ICLR) director plans 569,625 stock sale - Stock Titan
ICON (NASDAQ: ICLR) director plans to sell thousands of shares in 2026 - Stock Titan
ICON plc Q2 2026 Earnings: EPS Narrowly Misses Estimate as Stock Edges LowerProduct Revenue Analysis - careplusvn.com
ICON plc (NASDAQ: ICLR) director plans $876K sale after $138K trade - Stock Titan
ICON plcOrdinary Shares (Nasdaq:ICLR) Detailed Stock Data - The Chronicle-Journal
ICON plc (ICLR) Stock Analysis: Unpacking a 9.6% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
ICON plc Stock Price: ICLR Stock Chart, Market Cap & News Today - CoinGecko
A Look at Icon PLC (ICLR) After 3.9% Gain -- GF Value $207.68 vs Price $165.69 - GuruFocus
ICON PLC (NASDAQ: ICLR) Releases Unaudited Interim Financial Statements in September 9 Filing - kalkinemedia.com
ICON taps Anthropic and Microsoft as it puts clinical-trial agents into production - R&D World
[6-K] ICON PLC Current Report (Foreign Issuer) - Stock Titan
Is Icon PLC (ICLR) a Bargain After 4.1% Drop? GF Value Says Unde - GuruFocus
ICON plc (ICLR) Stock Report: Evaluating a 12.56% Potential Upside Amidst Healthcare Sector Expansion - DirectorsTalk Interviews
Long term debt to total equity ratio of ICON Plc – HAM:IJF - TradingView
Icon plc stock holds steady as Q2 2026 results support full-year guidance - ad-hoc-news.de
ICON Plc (ICLR) Stock Analysis: Exploring Growth Potential With A 9.14% Upside - DirectorsTalk Interviews
How ICON’s Mixed Q1 Earnings and Reaffirmed 2026 Outlook Could Impact ICON (ICLR) Investors - sahmcapital.com
Icon PLC (ICLR) Up 2.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Icon (ICLR) Stock Forecast and Price Target 2026 $ICLR - MarketBeat
ICON plc (ICLR) Stock Analysis: Navigating Growth in Diagnostics & Research with a 7.74% Upside - DirectorsTalk Interviews
ICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and Sustainability - BioSpace
ICON plc (ICLR) posts top-1% ESG score and 73% emissions cut - Stock Titan
A Look at Icon PLC (ICLR) After 3.2% Gain -- GF Value $208.22 vs Price $172.49 - GuruFocus
ETFs Investing in ICON Plc Stocks - TradingView
ICON plc (NASDAQ: ICLR) swaps secured loans for $2.15B in new notes - Stock Titan
White & Case advises ICON on its US$2.15 billion notes offering and related secured debt refinancing - White & Case LLP
6-K: Icon PLC | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
Icon PLC (ICLR) Shares Surge 3.9% -- What GF Score of 93 Tells I - GuruFocus
ICON plc (ICLR) Stock Analysis: Strong Buy Ratings and 13.74% Potential Upside Highlight Investment Appeal - DirectorsTalk Interviews
Icon CEO awarded $3.7m in shares as company emerges from turmoil - Irish Independent
Does ICON’s Shift to an Unsecured Capital Structure Reshape the Bull Case for ICLR? - Sahm
Finanzdaten der Icon Plc-Aktie (ICLR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Icon Plc-Aktie (ICLR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| CLIMAX JOHN DR | Director |
Sep 16 '26 |
Sale |
175.00 |
5,005 |
875,875 |
2,087 |
| McCague Eugene Pacelli | Director |
Sep 17 '26 |
Option Exercise |
125.74 |
3,255 |
409,284 |
7,066 |
| McCague Eugene Pacelli | Director |
Sep 17 '26 |
Sale |
175.00 |
3,255 |
569,625 |
3,811 |
| Murphy Ronan Martin | Director |
Sep 17 '26 |
Option Exercise |
125.74 |
5,005 |
629,329 |
8,852 |
| Murphy Ronan Martin | Director |
Sep 17 '26 |
Sale |
175.00 |
5,005 |
875,875 |
3,847 |
0.97%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):